Biopharmaceutical Company Announces Issuance of New Chinese Patent For Ebola Virus Treatment

For the pharmaceutical industry and global public health, RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company based in Tel-Aviv, Israel, and Raleigh, North Carolina, has announced the issuance of a new Chinese patent for Opaganib. This novel therapeutic agent, designed for the treatment of Ebola Virus Disease among other potential indications, now enjoys patent protection in China through 2035. This milestone marks a pivotal moment not only for RedHill but also for the broader medical community engaged in the battle against deadly viral diseases like Ebola. $Redhill Biopharma(RDHL.US)$